Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 192

1.

Krestin (PSK).

Tsukagoshi S, Hashimoto Y, Fujii G, Kobayashi H, Nomoto K, Orita K.

Cancer Treat Rev. 1984 Jun;11(2):131-55. Review.

PMID:
6238674
2.

Competitive action of a biological response modifier, PSK, on a humoral immunosuppressive factor produced in tumor-bearing hosts.

Matsunaga K, Morita I, Iijima H, Endo H, Oguchi Y, Yoshimura M, Fujii T, Yoshikumi C, Nomoto K.

J Clin Lab Immunol. 1990 Mar;31(3):127-36.

PMID:
1966997
3.

PSK as a chemopreventive agent.

Kobayashi H, Matsunaga K, Fujii M.

Cancer Epidemiol Biomarkers Prev. 1993 May-Jun;2(3):271-6. Review.

4.

Antitumor effect of PSK at a distant site: inductions of interleukin-8-like factor and macrophage chemotactic factor in murine tumor.

Ebina T, Murata K.

Jpn J Cancer Res. 1990 Dec;81(12):1307-13. Erratum in: Jpn J Cancer Res 1991 Feb;82(2):233.

PMID:
2126000
6.

[Restoration of depressed immune responses by PSK in C3H/He mice bearing the syngeneic X5563 tumor].

Matsunaga K, Morita I, Oguchi Y, Fujii T, Yoshikumi C, Nomoto K.

Gan To Kagaku Ryoho. 1986 Dec;13(12):3453-60. Japanese.

PMID:
3789756
7.

Enhancement of effector cell activities in mice bearing syngeneic plasmacytoma X5563 by a biological response modifier, PSK.

Matsunaga K, Iijima H, Aota M, Oguchi Y, Fujii T, Yoshikumi C, Nomoto K.

J Clin Lab Immunol. 1992 Jan;37(1):21-37.

PMID:
1339233
8.

Enhancement of the antitumor effect by the concurrent use of a monoclonal antibody and the protein-bound polysaccharide PSK in mice bearing a human cancer cell line.

Kanoh T, Saito K, Matsunaga K, Oguchi Y, Taniguchi N, Endoh H, Yoshimura M, Fujii T, Yoshikumi C.

In Vivo. 1994 Mar-Apr;8(2):241-5.

PMID:
7919129
9.

[Effect of PSK on tumor-specific immunity induced by MMC-treated syngeneic tumor cells].

Tsuru S, Oguchi M, Mashiko M, Aiso S, Zinnaka Y, Nomoto K.

Gan To Kagaku Ryoho. 1982 Sep;9(9):1634-9. Japanese.

PMID:
6820923
10.

[Restoration of immunologic responsiveness by PSK in tumor-bearing animals].

Matsunaga K, Morita I, Oguchi Y, Fujii T, Yoshikumi C, Nomoto K.

Gan To Kagaku Ryoho. 1986 Dec;13(12):3468-75. Japanese.

PMID:
3789758
11.
12.

Effects of PSK, an antitumor protein-bound polysaccharide, on the surface charge of lymphocytes in X5563-bearing mice.

Hayashi H, Fujii T, Fujii M, Yoshikumi C, Kawai Y, Shimizu M, Iwaguchi T.

J Clin Lab Immunol. 1987 Sep;24(1):33-7.

PMID:
3681950
13.
14.

[Competitive effect of PSK against the immunosuppressive effect induced in the sera of mice bearing syngeneic tumors].

Matsunaga K, Morita I, Oguchi Y, Fujii T, Yoshikumi C, Nomoto K.

Gan To Kagaku Ryoho. 1986 Dec;13(12):3461-7. Japanese.

PMID:
3789757
15.

Polysaccharide krestin is a novel TLR2 agonist that mediates inhibition of tumor growth via stimulation of CD8 T cells and NK cells.

Lu H, Yang Y, Gad E, Wenner CA, Chang A, Larson ER, Dang Y, Martzen M, Standish LJ, Disis ML.

Clin Cancer Res. 2011 Jan 1;17(1):67-76. doi: 10.1158/1078-0432.CCR-10-1763. Epub 2010 Nov 10.

16.

Treatment with Krestin combined with mitomycin C, and effect on immune response.

Fujii T, Sugita N, Kobayashi Y, Saito K, Iijima H, Matsunaga K, Ando T, Oguchi Y, Morita I, Yoshikumi C, et al.

Oncology. 1989;46(1):49-53.

PMID:
2492652
18.
19.

Anticancer effects and mechanisms of polysaccharide-K (PSK): implications of cancer immunotherapy.

Fisher M, Yang LX.

Anticancer Res. 2002 May-Jun;22(3):1737-54. Review.

PMID:
12168863
20.

[Antitumor effect of PSK and its combined effect with CDDP on ovarian serous adenocarcinoma-bearing nude mice].

Ishii K, Kita T, Hirata J, Tode T, Kikuchi Y, Nagata I.

Nihon Sanka Fujinka Gakkai Zasshi. 1993 Apr;45(4):333-9. Japanese.

PMID:
8509669
Items per page

Supplemental Content

Write to the Help Desk